Search results
The guideline has attempted to devise effective strategies for the reduction of CVD that take a combined approach using both ‘high-risk’ and population approaches. 1.1.1 UPDATING THE EVIDENCE This guideline updates SIGN 97: Risk estimation and the prevention of cardiovascular disease to reflect the most recent evidence.
The current guideline provides comprehensive advice on prevention and management of VTE based on the evidence available to answer a set of key questions, listed in Annex 1. 1.1.2 EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM
SIGN guideline recommendations are available on the move with the award-winning SIGN app for iPhone, iPad, iPod Touch and Android phones and tablets. optimised for the latest operating systems; updated content; re-designed for improved legibility; send PDF button feature; split screen feature (iPad
30 sie 2024 · This 2024 guideline, developed by a multidisciplinary Task Force, updates the 2018 ESC/ESH guidelines on the management of arterial hypertension, using the most robust contemporary evidence.
30 sie 2024 · For patients with elevated BP and borderline increased predicted CVD risk by SCORE2/SCORE2-OP (5% to <10% over 10 years), up-classification of risk may be considered in the presence of sex-specific or shared non-traditional risk modifiers.
The 2020 ISH Global Hypertension Practice Guidelines were developed by the ISH Hypertension Guidelines Committee based on evidence criteria, (1) to be used globally; (2) to be fit for application in low and high resource settings by advis-ing on essential and optimal standards; and (3) to be concise, simplified, and easy to use.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular
